Abstract: Therapeutic chondrisome and mitoplast compositions and related methods are described.

Abstract: The disclosure provides, for example, single stranded, covalently closed DNA that does not form a double stranded structure longer than 100 base pairs. The ssDNA may encode an effector sequence, for instance a therapeutic protein. The ssDNA may comprise a nuclear targeting sequence (NTS). In some embodiments, the ssDNA shows decreased activation of the innate immune system compared to an otherwise similar dsDNA.

Abstract: Methods and compositions for modulating a target genome are disclosed.

Abstract: Methods and compositions for modulating a target genome are disclosed. This disclosure relates to novel compositions, systems and methods for altering a genome at one or more locations in a host cell, tissue or subject, in vivo or in vitro. In particular, the invention features compositions, systems and methods for inserting, altering, or deleting sequences of interest in a host genome.

Abstract: Therapeutic chondrisome compositions and related methods are described.

Abstract: Methods and compositions for modulating a target genome are disclosed.

Abstract: Methods and compositions for modulating a target genome are disclosed. The composition may comprise a first RNA encoding a polypeptide comprising a retrotransposase reverse transcriptase domain and a retrotransposase endonuclease domain. The composition may also comprise a second RNA comprising a sequence that binds the polypeptide and a heterologous object sequence. The composition may insert the sequence of the heterologous object sequence into a target DNA.

Abstract: This disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising a chemically modified cytosine nucleotide. In some embodiments, the dsDNA molecules comprise a therapeutic payload sequence. In some embodiments, the dsDNA molecules are resistant to endonuclease digestion and/or resistant to immune sensor recognition, and supports expression of a therapeutic payload encoded in the dsDNA molecules. The disclosure also provides, for example, pharmaceutical compositions comprising dsDNA molecules comprising a chemically modified cytosine nucleotide.

Abstract: This disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising a chemically modified uridine nucleotide. In some embodiments, the dsDNA molecules comprise a therapeutic payload sequence. In some embodiments, the dsDNA molecules are resistant to endonuclease digestion and/or resistant to immune sensor recognition, and supports expression of a therapeutic payload encoded in the dsDNA molecules. The disclosure also provides, for example, pharmaceutical compositions comprising dsDNA molecules comprising a chemically modified uridine nucleotide.

Abstract: Methods and compositions for modulating a target genome are disclosed.

Abstract: Methods and compositions for modulating a target genome are disclosed. For instance, the disclosure provides site-specific recombinases (e.g., serine recombinases, e.g., serine integrases) capable of directing insertion of an insert DNA, or portion thereof, into a desired site in a target genome.

Abstract: Methods and compositions for modulating a target genome are disclosed.

Abstract: Methods and compositions for modulating a target genome are disclosed. The composition may comprise a first RNA encoding a polypeptide comprising a retrotransposase reverse transcriptase domain and a retrotransposase endonuclease domain. The composition may also comprise a second RNA comprising a sequence that binds the polypeptide and a heterologous object sequence. The composition may insert the sequence of the heterologous object sequence into a target DNA.

Abstract: Methods and compositions for altering a genome at one or more locations in a host cell, tissue, or subject are disclosed.

Abstract: Preparations of glycan therapeutics, pharmaceutical compositions, dietary supplements and medical foods thereof are provided, and methods of using said glycan therapeutics, e.g. in cancer therapy.

Abstract: Methods and compositions for modulating a target genome are disclosed.

Abstract: Methods and compositions for modulating a target genome are disclosed.

Abstract: Therapeutic chondrisome and mitoplast compositions and related methods are described.

Abstract: Therapeutic chondrisome compositions and related methods are described.

Abstract: The invention provides, inter alia, systems and associated methods, for modifying DNA, such as the genome of a cell. The systems, in certain embodiments, encompass one or more tissue-specific expression-control sequences, such as promoters and microRNA binding sites in addition to a transposase (or a nucleic acid encoding the same) and a template nucleic acid comprising a sequence to be inserted into the genome of a cell, tissue, or subject.